NTLA
Intellia Therapeutics Inc

14,373
Mkt Cap
$1.55B
Volume
5.22M
52W High
$28.25
52W Low
$5.90
PE Ratio
-3.44
NTLA Fundamentals
Price
$12.84
Prev Close
$13.15
Open
$13.13
50D MA
$12.93
Beta
1.73
Avg. Volume
3.34M
EPS (Annual)
-$3.81
P/B
2.28
Rev/Employee
$179,498.67
$617.75
Loading...
Loading...
News
all
press releases
Take the Zacks Approach to Beat the Markets: Starbucks, Amgen, Allogene in Focus
ALLO, SBUX and AMGN highlight how Zacks strategies and portfolio picks are delivering strong gains despite recent market volatility.
Zacks·11d ago
News Placeholder
More News
News Placeholder
Intellia Therapeutics (NASDAQ:NTLA) Upgraded at Wall Street Zen
Wall Street Zen upgraded shares of Intellia Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday...
MarketBeat·14d ago
News Placeholder
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Average Recommendation of "Hold" by Brokerages
Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report) have received an average recommendation of "Hold" from the twenty-one analysts that are presently covering the stock, Marketbeat...
MarketBeat·15d ago
News Placeholder
ARK Investment Management LLC Trims Stake in Intellia Therapeutics, Inc. $NTLA
ARK Investment Management LLC lessened its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 8.4% in the third quarter, according to the company in its most recent filing with...
MarketBeat·16d ago
News Placeholder
Intellia Therapeutics (NASDAQ:NTLA) Upgraded at JonesTrading
JonesTrading raised Intellia Therapeutics from a "hold" rating to a "buy" rating and set a $29.00 price objective for the company in a research report on Wednesday...
MarketBeat·16d ago
News Placeholder
Intellia Therapeutics (NASDAQ:NTLA) Given New $48.00 Price Target at Canaccord Genuity Group
Canaccord Genuity Group cut their price objective on shares of Intellia Therapeutics from $54.00 to $48.00 and set a "buy" rating on the stock in a research report on Tuesday...
MarketBeat·17d ago
News Placeholder
Leerink Partners Issues Positive Forecast for Intellia Therapeutics (NASDAQ:NTLA) Stock Price
Leerink Partners lifted their price target on shares of Intellia Therapeutics from $27.00 to $29.00 and gave the company an "outperform" rating in a research note on Tuesday...
MarketBeat·17d ago
News Placeholder
Royal Bank Of Canada Issues Positive Forecast for Intellia Therapeutics (NASDAQ:NTLA) Stock Price
Royal Bank Of Canada lifted their price target on shares of Intellia Therapeutics from $9.00 to $15.00 and gave the company a "sector perform" rating in a research report on Tuesday...
MarketBeat·17d ago
News Placeholder
Wells Fargo & Company Issues Positive Forecast for Intellia Therapeutics (NASDAQ:NTLA) Stock Price
Wells Fargo & Company increased their target price on Intellia Therapeutics from $12.00 to $15.00 and gave the stock an "equal weight" rating in a research report on Tuesday...
MarketBeat·17d ago
News Placeholder
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Key PointsArk Invest bought shares of MercadoLibre, Intellia Therapeutics, and Generate Biomedicines on Monday...
Nasdaq News: Markets·17d ago
<
1
2
...
>

Latest NTLA News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.